Merck and Co. To Acquire Peleton Therapeutics in $2.2-Billion Deal
默克公司以22亿美元收购Peleton医疗公司
Merck& Co. has entered into a definitive agreement with Peleton Therapeutics, a clinical-stage biopharmaceutical company, under which Merck, through a subsidiary, will acquire all outstanding shares of Peleton for $1.05 billion upfront plus a further $1.15 billion contingent upon successful achievement of future regulatory and sales milestones for certain candidates.
默克公司(merck & Co.) 已与临床阶段生物制药公司 Peleton 医疗达成最终协议, 根据该协议,默克公司将通过其子公司以10.5亿美元的前期价格收购Peleton 的所有流通股, 另外追加11.5亿美元，视某些候选在未来实现监管和销售里程碑方面成功的成就为条件。
Peletonis focused on the development of small-molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate is PT2977, an oral HIF-2α inhibitor in late-stage development for renal cell carcinoma. PT2977 is currently being evaluated in Phase II clinical trials.
Peleton专注于开发针对缺氧诱导因子 2α (HIF-2α) 治疗癌症和其他非肿瘤疾病患者的小分子治疗候选物。Peloton 的主要候选药物是 PT2977, 一种口服HIF-2α抑制剂,用于肾细胞癌晚期。PT2977目前正处于临床试验中第二阶段的评估阶段。
Closing of the agreement is subject to conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The companies expect the acquisition to be completed in the third quarter of 2019.
达成协议需要取决于一些条件, 包括根据《哈特-斯科特-罗迪诺反垄断改进法案》和其他惯例条件，等待期届满。两家公司预计收购将于于2019年第三季度完成。
本文内容取自 Merck
关注PQE，了解最新医药器械行业前沿与法规动向
